Je was op zoek naar: gemcitabinom (Sloveens - Engels)

veja z gemcitabinom in paklitakselom (n=262)
gemcitabine plus

med terapijo z gemcitabinom mora biti dojenje prekinjeno.
breast-feeding must be discontinued during gemcitabine therapy.

zdravilo tarceva boste dobili v kombinaciji z gemcitabinom.
tarceva is given in combination with gemcitabine treatment.

rak trebušne slinavke (zdravilo tarceva v kombinaciji z gemcitabinom):
pancreatic cancer (tarceva administered concurrently with gemcitabine):

a 405 bolnikov ocenjenih v skupini, zdravljeni z zdravilom abraxane in gemcitabinom
a 405 patients assessed in abraxane/gemcitabine-treated group

adenokarcinom trebušne slinavke (zdravilo abraxane uporabljeno skupaj z gemcitabinom)
pancreatic adenocarcinoma (abraxane administered in combination with gemcitabine)

Če pride do razvoja teh učinkov, je potrebno razmisliti o prekinitvi terapije z gemcitabinom.
if such effects develop, consideration should be made to discontinuing gemcitabine therapy.

pri starejših bolnikih ali tistih z stanjem zmogljivosti 2 lahko razmislimo o monoterapiji z gemcitabinom.
gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.

rak trebušne slinavke (zdravilo tarceva v kombinaciji z gemcitabinom v študiji pa.3):
pancreatic cancer (tarceva administered concurrently with gemcitabine in study pa.3):

monoterapija z gemcitabinom se lahko uporabi pri starostnih bolnikih ali tistih s statusom učinkovitosti 2. “
gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.”

rak trebušne slinavke zdravilo tarceva je v kombinaciji z gemcitabinom indicirano za zdravljenje bolnikov z metastatskim rakom trebušne slinavke.
tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.

noben bolnik, zdravljen z zdravilom abraxane v kombinaciji z gemcitabinom, ni imel periferne nevropatije 4. stopnje.
no patients treated with abraxane in combination with gemcitabine had grade 4 peripheral neuropathy.

o pnevmonitisu so pri bolnikih, ki so prejemali sočasno zdravljenje z obsevanjem in/ali gemcitabinom, poročali zelo redko.
pneumonitis in patients receiving concomitant radiotherapy and/or gemcitabine has been reported very rarely.

pri bolnikih, ki so prejemali vinflunin v kombinaciji s cisplatinom, karboplatinom, kapecitabinom ali gemcitabinom, niso opazili farmakokinetičnih interakcij.
no pharmacokinetic interaction was observed in patients when vinflunine was combined with either cisplatin, carboplatin, capecitabine or gemcitabine.

od 17 primerov pnevmonitisa, o katerih so poročali pri bolnikih, zdravljenih z zdravilom abraxane skupaj z gemcitabinom, je bil pri dveh bolnikih izid smrten.
of the 17 cases of pneumonitis reported in patients treated with abraxane in combination with gemcitabine, 2 had a fatal outcome.

bolnike, ki se sočasno zdravijo z erlotinibom in gemcitabinom, je treba skrbno spremljati zaradi možnosti pojava toksičnosti, podobni intersticijski bolezni pljuč.
patients treated concurrently with erlotinib and gemcitabine should be monitored carefully for the possibility to develop ild-like toxicity.

paklitaksel, zlasti v kombinaciji z obsevanjem pljuč in/ali gemcitabinom, ne glede na časovno zaporedje, lahko prispeva k razvoju intersticialnega pnevmonitisa.
paclitaxel, particularly in combination with radiation of the lung and/or gemcitabine, irrespective of their chronological order, may contribute to the development of interstitial pneumonitis.

primere kardiorespiratornih obolenj in nepojasnjeno smrt so opazili pri bolnikih, zdravljenih z zdravilom portrazza v kombinaciji z gemcitabinom in cisplatinom, in pri bolnikih, ki so bili zdravljeni samo z gemcitabinom in cisplatinom.
cases of cardiorespiratory disorders and unexplained death were observed in patients treated with portrazza in combination with gemcitabine and cisplatin and in patients treated with gemcitabine and cisplatin alone.

v zdravljeni populaciji je bila mediana relativne intenzivnosti odmerka gemcitabina v skupini z zdravilom abraxane/gemcitabinom 75 %, v skupini z gemcitabinom pa 85 %.
for the treated population, the median relative dose intensity for gemcitabine was 75% in the abraxane/gemcitabine arm and 85% in the gemcitabine arm.

pri raku trebušne slinavke so zdravilo tarceva v kombinaciji z gemcitabinom proučevali pri 569 bolnikih z napredovalim, neoperabilnim (ki ga ni mogoče odstraniti s kirurškim posegom) ali metastatskim rakom trebušne slinavke.
in pancreatic cancer, tarceva in combination with gemcitabine has been studied in 569 patients with pancreatic cancer that was advanced, unresectable (that cannot be removed by surgery) or metastatic.